---
title: "Opioid use in Cancer Patients"
author: "Matthew Siddoway"
date: "`r Sys.Date()`"
output:
  github_document:
    toc: true
---

```{r setup, include=FALSE}
knitr::opts_chunk$set(echo = TRUE)
```
# ABSTRACT
Opioid responsiveness varies widely among cancer patients, and growing evidence suggests that genetic and phenotypic factors contribute to differences in analgesic efficacy (Baldwin et al., 2012; Klepstad et al., 2011). This study investigates whether variation at the rs12948783 genetic locus—as well as phenotypic variables such as sex and country of origin—influences normalized pain relief among European cancer patients treated with opioid medications. Using a simulated dataset modeled on the findings of Galvan et al. (2011), we conducted linear modeling and graphical analyses to evaluate associations between genotype and pain outcomes. Our results show clear differences in mean pain relief across genotypes and between minor-allele carriers and non-carriers, suggesting that genetic background may play a meaningful role in modulating opioid response. These findings support the growing movement toward personalized, genotype-informed pain management for cancer patients.

# BACKGROUND
Effective pain management in cancer patients remains a critical challenge, as individuals often exhibit substantial variability in their responses to opioid therapy. This variability can result from a combination of physiological, environmental, and genetic factors that influence both opioid metabolism and receptor function. Recent pharmacogenetic studies have emphasized the role of single nucleotide polymorphisms (SNPs) in genes associated with opioid signaling pathways in determining the efficacy and dosage requirements of pain treatment.
One influential study by Galvan et al. (2011) identified multiple genetic loci that modulate opioid therapy response in cancer patients across Europe. Their findings indicated that variants such as rs12948783 were significantly associated with differences in pain relief and opioid dose requirements, suggesting that specific genetic profiles can affect a patient’s analgesic sensitivity. These results highlight the importance of integrating genetic screening into clinical pain management to optimize therapeutic outcomes and minimize adverse effects.
Based on this evidence, the present study seeks to investigate how genetic and phenotypic factors influence pain management outcomes among European cancer patients treated with opioids. Specifically, we hypothesize that genetic variation at the rs12948783 locus, along with phenotypic variables such as sex and country, significantly affect normalized pain relief. We predict that carriers of the minor allele (AG or GG genotypes) will experience greater pain relief compared to AA homozygotes, reflecting enhanced opioid responsiveness.
Understanding these genetic and demographic determinants of opioid efficacy may provide valuable insights for the development of personalized pain management strategies, ultimately improving quality of life for cancer patients undergoing treatment.
# STUDY QUESTION and HYPOTHESIS

## Questions  
What effect does genetics and phenotypes have on pain management among European cancer patients who have been treated with opioids?

## Hypothesis 
Genetic variation in opioid receptor-related genes significantly affect pain relief and opioid requirements.
## Prediction
I predict that there will be certain phenotypes and genetics that correspond to lesser pain responses depending on the unique genetic makeup of each demographic.

# METHODS
This study analyzed a simulated dataset modeled after the pharmacogenomic structure reported in Galvan et al. (2011). Data included genotype at rs12948783, carrier status of the minor allele, normalized pain relief, sex, and country of origin.
After importing the dataset into R, boxplots were created to visualize pain relief differences across genotypes, while barplots summarized mean ± standard error pain relief values by genotype and carrier status.
All analyses were performed using readr, dplyr, and ggplot2 (Wickham et al., 2019).

```{r}
library(readr)
library(ggplot2)

data <- read_csv("epos_style_rs12948783_simulated_large.csv")

data$genotype <- as.factor(data$genotype)
data$sex <- as.factor(data$sex)
data$country <- as.factor(data$country)

sample_size <- min(5000, nrow(data))

model_data <- data[sample(nrow(data), sample_size), ]
model <- lm(norm_pain_relief ~ genotype + sex + country, data = model_data)
summary(model)

plot_data <- data[sample(nrow(data), sample_size), ]

ggplot(plot_data, aes(x = genotype, y = norm_pain_relief, fill = genotype)) +
  geom_boxplot(alpha = 0.7) +
  geom_jitter(width = 0.15, alpha = 0.4) +
  labs(
    title = "Effect of Genotype on Normalized Pain Relief",
    x = "Genotype (rs12948783)",
    y = "Normalized Pain Relief (%)"
  ) +
  theme_minimal()
```


```{r}

suppressPackageStartupMessages({ library(readr); library(dplyr); library(ggplot2) })


dat <- read_csv("epos_style_rs12948783_simulated_large.csv")
names(dat) <- make.names(trimws(names(dat)), unique = TRUE)

stopifnot(all(c("genotype","norm_pain_relief","carrier") %in% names(dat)))
dat$genotype <- as.factor(dat$genotype)
dat$carrier  <- as.factor(dat$carrier)
dat$pain     <- suppressWarnings(as.numeric(dat$norm_pain_relief))
dat <- dat[is.finite(dat$pain), , drop = FALSE]

summ <- dat %>%
  dplyr::group_by(genotype, carrier) %>%
  dplyr::summarise(
    n  = dplyr::n(),
    mn = mean(pain, na.rm = TRUE),
    sd = sd(pain,   na.rm = TRUE),
    se = ifelse(n > 1, sd / sqrt(n), 0),
    .groups = "drop"
  )

geno_order <- summ %>%
  dplyr::group_by(genotype) %>%
  dplyr::summarise(overall = mean(mn, na.rm = TRUE), .groups = "drop") %>%
  dplyr::arrange(dplyr::desc(overall)) %>%
  dplyr::pull(genotype) %>%
  as.character()
summ$genotype <- factor(summ$genotype, levels = geno_order)

dodge_w <- 0.75
p <- ggplot(summ, aes(x = genotype, y = mn, fill = carrier)) +
  geom_col(position = position_dodge(width = dodge_w), width = 0.7) +
  geom_errorbar(aes(ymin = mn - se, ymax = mn + se),
                position = position_dodge(width = dodge_w), width = 0.15) +
  geom_text(aes(label = paste0("n=", n), y = mn + se),
            position = position_dodge(width = dodge_w),
            vjust = -0.4, size = 3) +
  labs(
    title = "Normalized pain relief (mean ± SE) by genotype and carrier",
    x = "Genotype", y = "Mean normalized pain relief", fill = "Carrier"
  ) +
  theme_minimal()
print(p)

```



# DISCUSSION
The present study demonstrates that genetic variation at rs12948783, combined with demographic factors, influences normalized pain relief in a simulated European cancer cohort. These findings align with earlier empirical results showing that SNPs in opioid-related genes significantly impact analgesic outcomes (Galvan et al., 2011).
Both the boxplots and barplots indicate substantial differences in pain relief across genotypes and carrier groups, with minor-allele carriers generally exhibiting enhanced opioid responsiveness. These results are consistent with prior observations that certain alleles increase opioid receptor sensitivity or alter downstream signaling pathways (Baldwin et al., 2012).
Overall, these results reinforce the idea that pharmacogenomic screening may be a valuable tool in optimizing opioid prescribing and improving cancer pain management.

## Interpretation of boxplot
The boxplot revealed clear differences in the distribution of normalized pain relief between rs12948783 genotypes. Several genotypes demonstrated higher median pain relief, while others exhibited more variability, indicating inconsistent or reduced opioid response. The presence of overlapping yet distinct distributions supports the hypothesis that genotype contributes to inter-individual differences in opioid analgesia, consistent with trends reported by Galvan et al. (2011).

## Interpretation of the barplot
The barplot showed that minor-allele carriers consistently exhibited higher mean normalized pain relief than non-carriers across nearly all genotypes. Standard error bars were relatively small, and sample sizes (n-values) were large, indicating reliable mean estimates. This pattern mirrors patterns seen in real pharmacogenomic cohorts, where minor-allele carriers often experience enhanced opioid sensitivity (Klepstad et al., 2011).
These visual findings suggest that the minor allele at rs12948783 may confer increased analgesic responsiveness.

# CONCLUSION
This study supports the hypothesis that genetic and phenotypic factors influence opioid treatment outcomes among European cancer patients. Variation at the rs12948783 locus appears to be meaningfully associated with pain relief, with minor-allele carriers showing superior analgesic response. Sex and country of origin also contributed to pain relief variability.
Together, these findings highlight the potential clinical value of incorporating genetic information into pain management strategies and underscore the need for continued research in personalized opioid therapy.

# REFERENCES     

Baldwin, R. M., Ohlsson, S., Pedersen, R. S., et al. (2012). Increased morphine clearance in women: A population pharmacokinetic study. British Journal of Clinical Pharmacology, 74(3), 459–468.

Galvan, A., Skorpen, F., Klepstad, P., Fragoso, M., Ando, M., Nilsen, T., ... & Ciotti, P. (2011). Multiple loci modulate opioid therapy response for cancer pain. Clinical Cancer Research, 17(13), 4581–4587. https://doi.org/10.1158/1078-0432.CCR-10-3407

Klepstad, P., Fladvad, T., Skorpen, F., et al. (2011). Influence of genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. Pain, 152(5), 1139–1145.
R Core Team. (2024). R: A language and environment for statistical computing. R Foundation for Statistical Computing.

Wickham, H., Averick, M., Bryan, J., et al. (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686.


ChatGPT. OpenAI, version Jan 2025. Used as a reference for functions such as plot() and to correct syntax errors. Accessed `r Sys.Date()`.



